Associations of oseltamivir with neuropsychiatric and behavioral adverse events: A systematic review and meta-analysis [0.03%]
奥司他韦与神经精神和行为不良事件关联的系统评价和meta分析
Hye Su Jeong,Yeo Wool Lee,Taeho Greg Rhee et al.
Hye Su Jeong et al.
Background: Influenza causes approximately 3-5 million severe cases and 290,000-650,000 deaths annually, and oseltamivir is considered the first-line pharmacotherapy. Recent reports on neuropsychiatric events (NPEs) assoc...
Optimizing maribavir management: The role of health system specialty pharmacies in access, monitoring, and waste reduction [0.03%]
优化maribavir的管理：卫生系统专业药店在准入、监测和减少废物中的作用
Dustin R Donald,Autumn D Zuckerman,Kevin Dee et al.
Dustin R Donald et al.
Background: Cytomegalovirus (CMV) infection is a common complication in transplant recipients, with refractory or resistant infections making up a subset of this population. Maribavir, indicated for CMV infection that is ...
Recommendations for use and coverage of digital, binocular treatments for amblyopia [0.03%]
关于弱视数字和双目治疗方法的应用和覆盖范围的建议
Brenda L Bohnsack,James Bowerman,K David Epley
Brenda L Bohnsack
Amblyopia is the most common cause of vision impairment in children and presents as reduced visual acuity caused by suppression of neurologic signals from an eye. Traditional treatments include penalizing the better-seeing eye by occlusion,...
AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphoma [0.03%]
AMCP市场洞察：以滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤为重点的管理护理双特异性抗体方法
Bridget Flavin,Denise Wolff,Laura R Bobolts et al.
Bridget Flavin et al.
Bispecific antibodies (bsAbs) are an emerging treatment modality particularly in hematologic malignancies such as the non-Hodgkin lymphomas follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Although bsAbs offer opportuniti...
AMCP Market Insights: Navigating the rapidly changing landscape of ER+/HER2- metastatic breast cancer [0.03%]
AMCP市场洞察：驾驭ER+/HER2-转移性乳腺癌迅速变化的治疗格局
Bridget Flavin,Denise Wolff,Laura Bobolts et al.
Bridget Flavin et al.
Breast cancer is the most common cancer diagnosed in women in the United States, and its impact on both patients and their caregivers, particularly in advanced or metastatic disease, is substantial. Additionally, for the most common breast ...
AMCP real-world evidence standards: Overcoming barriers to using real-world evidence in US payer decision-making [0.03%]
美国支付方决策中使用真实世界证据的障碍及AMCP真实世界证据标准
Catherine M Lockhart,Elizabeth Powers,Brian Sweet et al.
Catherine M Lockhart et al.
Background: US payers are interested in incorporating real-world evidence (RWE) into their pharmaceutical coverage and reimbursement decisions. One barrier to using RWE to inform decisions is the lack of standards for RWE...
Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis [0.03%]
来自理赔数据的群体水平分析：肌侵袭性膀胱癌患者疾病复发的经济负担
Patrick Squires,Erin E Cook,Yan Song et al.
Patrick Squires et al.
Background: Bladder cancer is a common cancer with significant morbidity, mortality, and economic cost. Muscle-invasive bladder cancer (MIBC) is typically managed with radical cystectomy (RC). Despite its curative intent,...
Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma [0.03%]
daratumumab、硼替佐米、来那度胺和地塞米松与硼替佐米、来那度胺和地塞米松治疗适合移植的新诊断多发性骨髓瘤患者的成本效果分析
Santosh Gautam,Laura Morrison,Philippe Thompson-Leduc et al.
Santosh Gautam et al.
Background: The phase 3 PERSEUS trial demonstrated superior efficacy of daratumumab (D), bortezomib (V), lenalidomide (R), and dexamethasone (d) induction/consolidation followed by DR maintenance (DVRd/DR) vs VRd inductio...
Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation [0.03%]
适用于IPAY 2027医疗保险药品价格谈判的选定药物、治疗替代品和价格参考标准
Sean D Sullivan,Emma M Cousin,Kevin H Li et al.
Sean D Sullivan et al.
Background: On or before November 1, 2025, the Centers for Medicare & Medicaid Services (CMS) will report the agreed-upon negotiated prices (maximum fair prices [MFPs]) for the second round of up to 15 Medicare Part D dru...
Guideline adherence of xanthine oxidase inhibitor utilization to treat gout in primary care [0.03%]
primary care中嘌呤氧化酶抑制剂治疗痛风的使用指南依从性
Liza W Claus,Madison E Auten,Joseph J Saseen et al.
Liza W Claus et al.
Background: Gouty arthritis affects 3.9% of American adults and can be effectively managed using urate-lowering therapy initiated at a low dose and titrated to achieve a serum urate of less than 6 mg/dL, the "treat-to-tar...